IN FOCUS

Recently, Comvikin has completed its Series B financing. The investors in this round include Puhua Capital, Delian Capital, CDH Investments, Orient Renaissance Capital, and the renowned Moutai.
FINANCE
VIEW ALL
September 11, 2025
GenFleet Therapeutics to list on the Hong Kong Stock Exchange on the 19th, with anchor investors subscribing for USD 100 millionOn September 11, 2025, GenFleet Therapeutics released its global offering document, with CITIC Securities acting as the sole sponsor.
INNOVATIONS
VIEW ALL
September 11, 2025
World’s first anti-scar drug: Mabwell Biosciences’ IL-11 antibody targets trillion-yuan fibrosis and anti-aging marketsMabwell announced that its innovative IL-11 monoclonal antibody drug, 9MW3811, has been accepted by the NMPA for a Phase II clinical trial application targeting pathological scars. This marks the world’s first IL-11 targeted therapy to enter the clinical stage for the treatment of pathological scars.
MORE
September 09, 2025
Rongchang Bio applies for market launch of new drug for Sjögren's Syndrome September 08, 2025
The most competitive generic drug of the year has been approved againMNC CHINA LENS
VIEW ALL
September 08, 2025
Japanese pharmaceutical company's RMB 1.1 billion investment project kicks off, accelerating local innovation in ADC drug R&DDaiichi Sankyo, a Japanese pharmaceutical company, has announced the official commencement of construction on a new antibody-drug conjugate (ADC) manufacturing facility in Shanghai’s Zhangjiang area, with a total investment of approximately RMB 1.1 billion. As one of China’s first pilot projects for cross-border, segmented manufacturing of biologics, this initiative will be rooted in the Chinese market to establish a localized ADC production base, significantly enhancing the domestic supply capacity of ADC innovative drugs.
September 12, 2025
AstraZeneca's long-acting C5 complement inhibitor Weilirui® launched in China September 12, 2025
CSPC Holdings: HER2 Bispecific antibody submitted for marketing approval September 11, 2025
Eli Lilly's BTK Inhibitor Enters the Autoimmune Disease Therapeutic FieldMORE
September 02, 2025
AstraZeneca’s benralizumab files for new indication in China August 12, 2025
Pfizer China: Major Structural Adjustment AgainASPECTS
VIEW ALL
September 10, 2025
Maxwell achieves high-precision, standardized intelligent simulation prosthesis customizationMaxwell started its business with breast prostheses. Leveraging technologies such as digital design, 3D printing, and automated coloring processes, it has built an efficient, replicable, and highly personalized production system and is expanding into customized prosthetic ears, noses, and even robotic simulation skin.
September 12, 2025
In Vivo CAR-T Fuels Upstream Industry Players? September 09, 2025
HK$138 million: medical beauty giant bets on RNA therapyRESEARCH
VIEW ALL
September 04, 2025
Kaiyuan Securities: Tracking Global Cutting-Edge Progress in the Weight Loss Sector (II) — Orforglipron Leads the Global Small-Molecule GLP-1RA Race as Domestic Pipeline Value Gradually EmergesSmall-molecule GLP-1RAs offer numerous advantages, including low cost, unrestricted usage scenarios, and no need for cold-chain transportation, giving them broad development prospects. In the small-molecule GLP-1RA race, Eli Lilly and Company’s Orforglipron has completed global Phase III trials for both diabetes and obesity, maintaining a leading position worldwide. AstraZeneca’s AZD5004, Roche’s CT-996, Lilly’s Naperiglipron, and Terns’ TERN-601 have all entered Phase II, with overall progress advancing rapidly. Among domestic companies, Hengrui Pharma, Huadong Medicine, and Ascletis Pharma, among others, are actively building small-molecule GLP-1RA pipelines. In recent years, this track has witnessed multiple high-profile BD transactions, and its growth momentum continues to strengthen.

September 03, 2025
2025 Chemical Pharmaceutical Enterprises Organizational Efficiency ReportAs of August 8, 2025, Shunwei Consulting collected organizational effectiveness data for 158 publicly listed chemical pharmaceutical companies through databases such as iFind. Among these, 111 are finished-dosage chemical drug companies and 47 are active pharmaceutical ingredient (API) companies.
Considering both company influence and revenue, companies with negative net profit (e.g., BeOne Medicines, Nenter) were excluded. From the remaining A-share listed companies, the top 10 chemical pharmaceutical companies by revenue were selected as benchmark enterprises for organizational effectiveness analysis.
To provide a comprehensive view of the industry, the selected companies cover various segments: innovative drug R&D (e.g., Hengrui Medicine, Humanwell Healthcare), high-end generics and internationalized formulations (e.g., Fosun Pharma, Kelun Pharma), and specialty APIs and complex formulations (e.g., Apeloa Pharmaceuticals, Livzon Group).

September 02, 2025
Global Healthcare Investment and Financing Monthly Report for August 2025In August 2025, a total of 150 financing events occurred globally in the healthcare sector (excluding IPOs, private placements, etc.), with a disclosed total financing amount of approximately USD 3.647 billion (around RMB 26.032 billion), according to incomplete statistics from VCBeat. Among these, the domestic market recorded 81 financing events with a total disclosed amount of approximately USD 942 million, while the overseas market recorded 69 financing events totaling approximately USD 2.705 billion.
Compared with July 2025 in terms of transaction amounts, number of financing events, and focus on emerging fields, the number of global healthcare financing events in August 2025 increased by approximately 11.11% month-on-month, while the total financing amount fell sharply by about 47.27%.
Regarding large financing events, 10 deals exceeded USD 100 million this month, with a cumulative financing amount of USD 1.511 billion. Among these, 9 occurred overseas and 1 domestically. The 10 companies are:
Kriya Therapeutics – gene therapy drug developer
EliseAI – healthcare system developer
Strand Therapeutics – biopharmaceutical company
Minghui Pharma – innovative drug developer
Apreo Health – device developer for emphysema treatment
Wugen – cell therapy developer
SetPoint Medical – developer of novel bioelectronic medical therapies
Restor3d – 3D-printed implant supplier
Eight Sleep – sleep health service provider
Nudge – developer of ultrasonic phased-array equipment
AWARDS
VIEW ALL
July 05, 2025
Top innovative healthcare assets in China ranked for June 2025
May 10, 2025
Future Healthcare Rankings in China Top Ten Healthcare Industry Service Chain Companies in 2025
May 10, 2025
Future Healthcare Rankings in China Top Ten Innovative Medical and Health Services Companies in 2025
May 10, 2025
Future Healthcare Rankings in China Top Ten Pharmaceuticals and Biologics Companies in 2025EVENTS
VIEW ALL18
Aug

Hall A1005, ATLATL Innovation and Research Center, No. 1077 Zhangheng Road, Pudong New Area, Shanghai
August 18, 2025
Learn More 12
Aug

07
Aug

August 07, 2025
Learn More Subscribe to our Newsletter Now
Exclusive updates and insights on healthcare innovation and Chinese market straight to your inbox